ChiCTR1900022029 版本V1.1 版本创建时间2019/03/21 17:40:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900022029 

最近更新日期:

Date of Last Refreshed on:

2019-03-21 17:34:07 

注册时间:

Date of Registration:

2019-03-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

重症患者合并心脏疾患预后分析的回顾性研究

Public title:

A retrospective study for the prognosis factors of critically ill patients with heart disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

重症患者合并心脏疾病预后分析的回顾性研究

Scientific title:

A retrospective study for the prognosis factors of critically ill patients with heart disease

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

唐艳 

研究负责人:

唐艳 

Applicant:

TangYan 

Study leader:

TangYan 

申请注册联系人电话:

Applicant telephone:

+86 13518508833

研究负责人电话:

Study leader's
telephone:

+86 13518508833

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

17518478@qq.com

研究负责人电子邮件:

Study leader's E-mail:

17518478@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国贵州省贵阳市北京路贵医街28号

研究负责人通讯地址:

中国贵州省贵阳市北京路贵医街28号

Applicant address:

28 Guiyi Street, Beijing Road, Guiyang, Guizhou, China

Study leader's address:

28 Guiyi Street, Beijing Road, Guiyang, Guizhou, China

申请注册联系人邮政编码:

Applicant postcode:

550004

研究负责人邮政编码:

Study leader's postcode:

550004

申请人所在单位:

贵州医科大学附属医院

Applicant's institution:

Affiliated Hospital of Guizhou Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2019015K

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

贵州医科大学附属医院药物临床试验伦理委员会

Name of the ethic committee:

The Clinical Trial Ethic Committee of the Affiliated Hospital of Gui Zhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2019-02-12 00:00:00

伦理委员会联系人:

王艺明

Contact Name of the ethic committee:

Yiming Wang

伦理委员会联系地址:

贵阳市北京路贵医街28号

Contact Address of the ethic committee:

28 Guiyi Street, Beijing Road, Guiyang, Guizhou, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

贵州医科大学附属医院重症医学科

Primary sponsor:

The Department of Critical Care Medicine of Affiliated Hospital of Guizhou Medical University

研究实施负责(组长)单位地址:

贵州省贵阳市北京路贵医街28号

Primary sponsor's address:

28 Guiyi Street, Beijing Road, Guiyang, Guizhou

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州

市(区县):

贵阳

Country:

China

Province:

Guizhou

City:

Guiyang

单位(医院):

贵州医科大学附属医院重症医学科

具体地址:

云岩区贵医街28号

Institution
hospital:

The Department of Critical Care Medicine of Affiliated Hospital of Guizhou Medical University

Address:

28 Guiyi Street, Yuyan District

经费或物资来源:

研究生补助津贴

Source(s) of funding:

Graduate experiment allowance

研究疾病:

重症心脏疾病  

Target disease:

critically ill patients with heart diseases

研究疾病代码:

Target disease code:

研究类型:

基础科学研究

Study type:

Basic Science

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

调查重症心脏疾患的一般流行病学特征;探究重症医学科心脏疾患的危险因素、了解临床处理策略,同时明确这些危险因素与心脏疾患预后的关系。进而有效降低此类患者在重症医学科死亡风险和病死率,早期预警、减少患者住ICU时间、住院费用及相关医疗费用等。  

Objectives of Study:

The aim of this study is to investigate the general epidemiological characteristics of heart diseases patients in intensive care units and to have a good command of clinical strategies.At the same time,we need to explore the relationship between these risk fators and the prognosis of cardiac diseases in critical care medicine.Hence we can reduce the rates and risks of death with these kind of diseases effectively, also the length of stay in ICU and fees .

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

① 年龄≥18岁;② 合并有心脏疾病的重症患者(无论是入ICU已明确诊断心脏疾病,或是入ICU继发心脏疾病);③ 住ICU时间≥48h;④ 一年内住ICU次数≥2次,取第一次临床资料。

Inclusion criteria

① Aged 18 years and above; ② Critically ill patients with heart diseases ; ③ Lenth of stay in ICU is no less than 48h; ④ Anyone whose hospitalization times is more than two in 1 year,we will select the first time clinical datas.

排除标准:

Exclusion criteria:

No

研究实施时间:

Study execute time:

From 2019-04-01 00:00:00 To 2019-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-04-01 00:00:00 To 2019-12-31 00:00:00

干预措施:

Interventions:

组别:

死亡组

样本量:

200

Group:

death group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

存活组

样本量:

600

Group:

survival group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

肥胖组

样本量:

350

Group:

obesity group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

正常组

样本量:

450

Group:

normal group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

高血尿酸组

样本量:

250

Group:

Hyperuricemia group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

非高血尿酸组

样本量:

550

Group:

non-Hyperuricemia

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州省 

市(区县):

贵阳市 

Country:

China

Province:

guizhou

City:

guiyang

单位(医院):

贵州医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated hospital of Guizhou Medical University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

性别

指标类型:

主要指标

Outcome:

gender

Type:

Primary indicator

测量时间点:

入院时

测量方法:

收集

Measure time point of outcome:

when is admitted to Hospital

Measure method:

check

指标中文名:

年龄

指标类型:

主要指标

Outcome:

age

Type:

Primary indicator

测量时间点:

入院时

测量方法:

查阅

Measure time point of outcome:

admitted to Hospital

Measure method:

check

指标中文名:

体重指数

指标类型:

主要指标

Outcome:

BMI

Type:

Primary indicator

测量时间点:

入ICU时

测量方法:

查阅+计算

Measure time point of outcome:

admitted to Hospital

Measure method:

check and calculate

指标中文名:

急性生理与慢性健康评分

指标类型:

主要指标

Outcome:

Acute Physiology and Chronic Health Evaluation

Type:

Primary indicator

测量时间点:

入icu24 h内

测量方法:

评分

Measure time point of outcome:

At the patient stay in ICU in fast 24 hours

Measure method:

score

指标中文名:

生化指标

指标类型:

主要指标

Outcome:

Biochemical indicators

Type:

Primary indicator

测量时间点:

住icu前48h

测量方法:

实验室检测

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine

Type:

Primary indicator

测量时间点:

住ICU前48h

测量方法:

实验室检测

Measure time point of outcome:

Measure method:

指标中文名:

住ICU时间

指标类型:

主要指标

Outcome:

length of stay in ICU

Type:

Primary indicator

测量时间点:

住ICU期间

测量方法:

查阅

Measure time point of outcome:

days in ICU

Measure method:

check

指标中文名:

治疗费用

指标类型:

主要指标

Outcome:

cost

Type:

Primary indicator

测量时间点:

住ICU期间

测量方法:

查阅

Measure time point of outcome:

days in ICU

Measure method:

check

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 不限 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2019年12月;上传到ResMan临床试验公共管理平台, http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

December 2019,we can upload the metadata;ResMan, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:使用病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

we use case record form to collect data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-03-21 17:33:50